Ipamorelin

Ipamorelin is a peptide-selective agonist of growth hormone releasing peptides/growth hormone secretagogue receptors (GHS) and a growth hormone secretagogue.

Ipamorelin is a pentapeptide (AIb-his-D-2-NAL-D-Phit-Lys-NH2) that has shown high GH-releasing potency and efficacy in vitro and in vivo. As a result of a major chemical program, ipamorelin was found in a range of compounds lacking Ala-Trp, the central dipeptide of growth hormone releasing peptide (GHRP) -1.

Ipamorelin, also known as NNC-26-0161, is a a ghrelin mimetic. Ipamorelin counteracts glucocorticoid-induced decrease in bone formation of adult rats. Ipamorelin may ameliorate the symptoms in patients with POI. Ipamorelin accelerates gastric emptying in a rodent model of postoperative ileus through the stimulation of gastric contractility by activating a ghrelin receptor-mediated mechanism involving cholinergic excitatory neurons.

Nou gen anpil faktori-wo kalite ak gwo koperasyon, ki ka ba ou bon jan kalite pwodwi ak pri konpetitif. Epi nou ka bay tou rabè pou acha esansyèl. Epi nou kolabore ak anpil konpayi transpò machandiz pwofesyonèl, ka delivre pwodwi san danje epi san pwoblèm nan men ou. Tan livrezon se sou 3-20 jou apre konfimasyon peman an.

In vitro experiments, ipamorelin released GH from primary rat pituitary cells with similar efficacy to GHRP-6. Pharmacological analyses using GHRP and growth hormone-releasing hormone (GHRH) antagonists clearly show that, like GHRP-6, Ipamorelin /Ipamorelin stimulates GH release through GHRP-like receptors.